KING PHARMACEUTICALS INC's Net Worth
$47.6 Million
Who is KING PHARMACEUTICALS INC?
KING PHARMACEUTICALS INC has an estimated net worth of $47.6 Million. This is based on reported shares across multiple companies, which include PALATIN TECHNOLOGIES INC, and NOVAVAX INC.
SEC CIK
KING PHARMACEUTICALS INC's CIK is 0001047699
Past Insider Trading and Trends
2004 was KING PHARMACEUTICALS INC's most active year for acquiring shares with 1 total transactions. KING PHARMACEUTICALS INC's most active month to acquire stocks was the month of June. 2004 was KING PHARMACEUTICALS INC's most active year for disposing of shares, totalling 4 transactions. KING PHARMACEUTICALS INC's most active month to dispose stocks was the month of June. 2004 saw KING PHARMACEUTICALS INC paying a total of $0.00 for 3,775,610 shares, this is the most they've acquired in one year. In 2004 KING PHARMACEUTICALS INC cashed out on 4 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
PALATIN TECHNOLOGIES INC (PTN) Snapshot price: $1.48
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NOVAVAX INC (NVAX) Snapshot price: $11.6
InvestorKING PHARMACEUTICALS INC owns 4,100,931 units of Common Stock which is worth $47,570,799.60. In the year 2004 KING PHARMACEUTICALS INC filed a total of 1 filing.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +1,160.58% | 3.78M |
—
|
—
| 4.1M |
Jul 16
| |||
| No matching records found | |||||||||